These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28262770)

  • 1. Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens.
    Pinto-Cardoso S; Lozupone C; Briceño O; Alva-Hernández S; Téllez N; Adriana A; Murakami-Ogasawara A; Reyes-Terán G
    Sci Rep; 2017 Mar; 7():43741. PubMed ID: 28262770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Decline in HIV-1 Drug Resistance in Heavily Antiretroviral-Experienced Patients Is Associated with Optimized Prescriptions in a Treatment Roll-Out Program in Mexico.
    Calva JJ; Larrea S; Tapia-Maltos MA; Ostrosky-Frid M; Lara C; Aguilar-Salinas P; Rivera H; Ramírez JP
    AIDS Res Hum Retroviruses; 2017 Jul; 33(7):675-680. PubMed ID: 28094565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
    Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
    Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
    Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
    HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.
    Borget MY; Diallo K; Adje-Toure C; Chorba T; Nkengasong JN
    J Clin Virol; 2009 May; 45(1):72-5. PubMed ID: 19375979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients.
    Imahashi M; Ode H; Kobayashi A; Nemoto M; Matsuda M; Hashiba C; Hamano A; Nakata Y; Mori M; Seko K; Nakahata M; Kogure A; Tanaka Y; Sugiura W; Yokomaku Y; Iwatani Y
    Sci Rep; 2021 Jan; 11(1):960. PubMed ID: 33441754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon.
    Abange WB; Martin C; Nanfack AJ; Yatchou LG; Nusbacher N; Nguedia CA; Kamga HG; Fokam J; Kennedy SP; Ndjolo A; Lozupone C; Nkenfou CN
    Sci Rep; 2021 Apr; 11(1):7666. PubMed ID: 33828220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
    Braithwaite RS; Kozal MJ; Chang CC; Roberts MS; Fultz SL; Goetz MB; Gibert C; Rodriguez-Barradas M; Mole L; Justice AC
    AIDS; 2007 Jul; 21(12):1579-89. PubMed ID: 17630553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine.
    Ray S; Narayanan A; Giske CG; Neogi U; Sönnerborg A; Nowak P
    ACS Infect Dis; 2021 May; 7(5):1104-1115. PubMed ID: 33346662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy and bone mineral measurements in HIV-infected youths.
    Zuccotti G; Viganò A; Gabiano C; Giacomet V; Mignone F; Stucchi S; Manfredini V; Marinacci F; Mora S
    Bone; 2010 Jun; 46(6):1633-8. PubMed ID: 20211284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.